Predictive value of ibutilide response for postoperative recurrence following catheter ablation in persistent atrial fibrillation: a retrospective study

伊布利特疗效对持续性房颤导管消融术后复发的预测价值:一项回顾性研究

阅读:2

Abstract

OBJECTIVE: This study investigated efficacy of intraoperative ibutilide administration for cardioversion of persistent atrial fibrillation (AF) during catheter ablation and evaluated predictive factors for postoperative AF recurrence. METHODS: A retrospective analysis was conducted involving 111 patients with persistent AF who underwent radiofrequency catheter ablation. Patients who failed to restore sinus rhythm after ablation received intravenous ibutilide (1-2 mg). Patients achieving sinus rhythm post-ibutilide administration were categorized as responders, while non-responders underwent electrical cardioversion. Clinical data were collected, and logistic regression was utilized to identify factors associated with ibutilide response and postoperative AF recurrence. RESULTS: Sinus rhythm was restored by ibutilide in 73 patients (65.7%). Non-response to ibutilide was independently associated with longer AF duration (OR = 1.82), diabetes ellitus (OR = 2.27), coronary artery disease (OR = 2.56), increased ST2 (OR = 1.08), larger left atrial diameter (LAD) (OR = 1.25), elevated NT-proBNP (OR = 1.01), and higher CHA2DS2-VASc scores (OR = 1.96; all P < 0.05). AF recurrence within 3 months post-ablation was independently predicted by intraoperative ibutilide non-response (OR = 5.317), older age (OR = 1.213), diabetes mellitus (OR = 0.14), increased LAD (OR = 1.211), elevated ST2 (OR = 1.139), elevated hs-CRP (OR = 1.276), and higher CHA(2)DS(2)-VASc scores (OR = 2.736; all P < 0.05). CONCLUSION: Intraoperative ibutilide responsiveness significantly predicts postoperative AF recurrence in patients undergoing catheter ablation for persistent AF. Assessing ibutilide response may enhance risk stratification and guide personalized treatment strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。